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Abstract 
Introduction. There are not many conditions in which the last few decades have brought such 
a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A 
number of disease modifying treatments (DMTs) are presently available for the treatment of 
the inflammatory phase of this disabling disease; however, the need for treating 
neurodegeneration and halting the progression of disability is still unmet.  
Areas covered: In this paper we review the available information on existing and emerging 
DMTs and we discuss their place within the context of different treatment strategies in MS, 
Expert Commentary: The future of MS treatments should include the development of new 
treatment strategies tackling disease progression, together with a better understanding of the 
side-effects and the best sequential strategy of implementation of available and emerging drugs. 
Keywords 
Multiple sclerosis, immunomodulation, monoclonal antibodies, remyelination, repurposing 
 
  
3 
 
Introduction 
Multiple sclerosis (MS) is a chronic, immune-mediated condition causing inflammation and 
neurodegeneration in the brain and spinal cord and the most common non-traumatic cause of 
neurological disability in young people in the western world [1]. In most patients, MS initially 
has a relapsing–remitting course (RRMS) with bouts of inflammation (relapses) and periods of 
remission. In the majority of people with MS, the relapsing course will later be followed by a 
secondary progressive phase (SPMS) [2]. In around 15% of cases, the disease progresses from 
the beginning with a primary progressive course without superimposed relapses (PPMS) [2]. 
More recent classifications put emphasis on the inflammatory activity which can be present at 
all stages of the disease and can be targeted with disease-modifying treatments (DMTs) [3]. 
A number of DMTs are currently available for the treatment of RRMS and their aim is to 
decrease the relapse rate and the inflammation within the central nervous system (CNS) [4]. 
The past 25 years have brought important changes in the treatment for MS. After several years 
in which first-line injectable DMTs interferon beta (IFNβ) and glatiramer acetate (GA) were 
the main treatment options, new medications with different regimens became available. The 
first oral DMT, fingolimod, was approved in 2010 in the US and soon after that in Europe. A 
number of other oral agents have been approved since or are currently in phase III trials or are 
due to be submitted to the regulatory agencies for approval [5]. Three monoclonal antibodies 
are now approved for MS treatment, and others are also in late stage development. 
Nevertheless, the challenges raised by the protracted course of the disease, the presence of 
neurodegeneration in all MS stages and the pathological burden (demyelination and axonal 
loss) inflicted over time by both inflammation and neurodegeneration raise challenges that are 
not yet completely tackled by the current therapies. In other words, despite a real breakthrough 
in treating MS, the available therapies are far from having sorted out the current unmet needs 
raised by the complexity of MS. Here we provide an outline of the actual treatment landscape 
in MS and some prospects on its future development. 
 
Expert commentary 
Approved treatments in MS 
Injectable drugs 
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Three IFNβ preparations are in widespread use as first-line DMTs for relapsing MS (RRMS 
and SPMS with relapses) and in some countries for clinically isolated syndrome (CIS). Each 
of them was licensed following single multicenter, double-blind, placebo-controlled, phase III 
trials [6]. Two of these medications require subcutaneous administration and one is given 
intramuscularly. GA (Copaxone®) is a four amino acid synthetic copolymer based on the 
composition of myelin basic protein [7]. GA was approved after a single phase III multicenter 
randomized placebo-controlled clinical trial [8]. GA is approved for RRMS and, in some 
countries, for patients with CIS. IFNβ and GA have different immunomodulatory effects but 
relatively comparable efficacy, reducing the relapse rate (RR) by approximately 30% [9]. Data 
from a large observational cohort study recently showed that treatment with IFNβ and GA 
reduces disability progression measured by EDSS scores over 6 years of treatment [10]. Both 
IFNΒ and GA are generally safe and well tolerated. Nevertheless, both IFNβ and GA require 
regular, long-term, self-injections. Side effects of IFNβ preparations include flu-like 
symptoms, an increase in liver enzymes, and injection-site reactions. Side effects of GA include 
local injection site reactions and post-injection reactions which occur in about 15% of people 
[11]. Issues of adherence and tolerance may therefore reduce the likelihood of achieving 
durable treatment efficacy [12]. 
Approved therapies such as the humanized antibodies natalizumab, alemtuzumab [13] and 
daclizumab, and the currently less used, cytostatic agent mitoxantrone are more effective but 
their use is associated with safety concerns. These drugs are administered parenterally and can 
have potentially severe side effects [e.g. progressive multifocal leukoencephalopathy (PML) 
for natalizumab; autoimmune-associated conditions for alemtuzumab; liver injury, colitis and 
skin reactions for daclizumab; cardiotoxicity and acute leukemia for mitoxantrone]. They are, 
therefore, reserved for the treatment of highly active MS. 
Natalizumab is a humanized recombinant monoclonal antibody directed against α4-integrin 
[13]. Natalizumab interferes with leukocyte migration from the peripheral blood into the CNS 
by preventing its binding via α4-integrin to the vascular cell adhesion molecule (VCAM) on 
endothelial cells [13]. This step has an impact on CNS inflammation as it blocks the adhesion 
and subsequent migration of lymphocytes across the blood–brain barrier (BBB). The drug was 
suspended in 2005 by the manufacturer [15] following two cases of PML in the SENTINEL 
trial in which it was given in combination with intramuscular IFNβ 1a [14]. In the pivotal 
placebo-controlled phase III trial which led to its approval natalizumab administered in the 
dose of 300 mg intravenously (i.v.) monthly reduced RR by 68% and sustained progression of 
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disability at 2 years by 42% [15]and MRI activity by 92% [16]. Natalizumab was reintroduced 
in 2006 with revised labelling and after the introduction of risk management programs [17]. 
The PML risk stratification for people with MS on natalizumab takes into account duration of 
treatment, prior immunosuppressant use and the anti- JC virus (JCV) antibody status reflecting 
infection with JCV [18,19]. This is allowing further risk stratification during natalizumab 
treatment [20]. In 4- to 6% of cases natalizumab treatment may induce the formation of 
persistent neutralising antibodies (NABs), usually within the first 12 months. The NABs are 
associated with higher rates of infusion-related adverse events and can lower the efficacy of 
the treatment [21]. 
Alemtuzumab is a humanized monoclonal antibody targeting CD52 expressed on lymphocytes, 
natural killer (NK) cells, monocytes, and some granulocytes [22,23]. Alemtuzumab produces 
rapid and profound lymphopenia lasting for years via antibody-dependent cellular cytotoxicity 
[13]. Alemtuzumab was compared to IFNβ-1a administered subcutaneously three times a week 
in two phase III trials of RRMS [24,25]. Alemtuzumab reduced the annualised relapse rate 
(ARR) by 49%–55%, MRI gadolinium enhancing lesions by 61%–63% and the rate of 
disability progression by 30%–42% [25,26]. The major safety concern with alemtuzumab are 
the autoimmune conditions (cumulative risk between 22% and 47%) [27,28] involving mainly 
the thyroid gland and blood cells (thrombocytopenia, hemolytic anemia, and pancytopenia), 
and nephropathies (in 0.3% of patients [29]). Prophylaxis of herpetic infections with oral 
acyclovir is required during and for 28 days after alemtuzumab infusion [28]. In Europe 
alemtuzumab is licensed as a first-line medication in active RRMS, however some neurologists 
would use it as a second-line drug because of the risk of secondary autoimmunity [21]. 
Daclizumab is a humanized neutralizing monoclonal antibody against the interleukin-2 (IL-2) 
receptor subunit CD25 on T cells [30]. Its effect on reducing CD25+ T cells is minimal but it 
expands CD56 bright NK cells and this correlates with the clinical effect [30]. Daclizumab is 
given either intravenously once every four weeks or subcutaneously once every four weeks 
(daclizumab high-yield process, DAC HYP). Daclizumab showed promising effects on MRI 
outcomes in randomized double-blind trials (two phase II, one phase III trial) [31-33] either as 
add-on therapy to IFNΒ-beta1a or placebo, and there were no indications of rebound effects 
after treatment interruption. In a phase III trial DAC HYP 150 mg was compared to 
intramuscular IFNΒ beta-1a and led to a 45% reduction in AAR but no statistically significant 
difference in the reduction of sustained disability. An extension phase is ongoing. There had 
been two deaths in the phase II trials (one from a psoas abscess and one from autoimmune 
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hepatitis) and one death in the DAC HYP not deemed to be related to the medication. The 
safety profile includes an increased incidence of cutaneous adverse events, serious cutaneous 
events, serious infections and elevations in liver function tests [33]. The cutaneous effects are 
distinctive adverse events of daclizumab. A review of the cutaneous adverse events in the 
DECIDE trial has recently been published [34]. Cortese et al. followed 31 participants in the 
phase I study of DAC-HYP (NCT01143441) over 42 months and observed cutaneous adverse 
events in 77% of patients treated with daclizumab[35]. The majority of skin events consisted 
of patches of eczema requiring no treatment [35], while moderate to severe rash (some with 
psoriasiform phenotype) developed in 19% and required treatment discontinuation in 13%. The 
skin biopsies from the lesions had nonspecific features of eczematous dermatitis, with 
important CD56+ lymphocytic infiltrates [35]which were not related to the clinical severity 
and with no histopathologic post-treatment changes [35]. 
Daclizumab (Zinbryta©) has very recently been approved by the FDA for RRMS [36]. 
Daclizumab should be given to patients who have had an inadequate response to two or more 
MS drugs. Because of the risk of side effects, daclizumab has a boxed warning and is available 
only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy 
[36]. Monitoring of liver function is required before commencing on daclizumab and monthly 
before each dose, and then for up to six months after the last dose [36]. The boxed warning 
highlights the risk of severe liver injury which could be potentially fatal, of non-infectious 
colitis, skin reactions, and lymphadenopathy [36]. 
Mitoxantrone is an anthracenedione that inhibits type II topoisomerase and disrupts DNA 
synthesis. Mitoxantrone was approved by the FDA in 2000 for rapidly worsening RRMS or 
SPMS after several clinical trials [37,38]. Mitoxantrone can cross the disrupted BBB and may 
induce microglial death as shown by in vitro studies [39]. Mitoxantrone is given in infusions 
at doses of 12 mg/m2 monthly however the cumulative dose is limited due to cardiologic and 
hematologic adverse effects. The use of mitoxantrone has rapidly decreased due to the risk of 
severe complications such as acute leukemia [40] and the increasing number of alternative 
highly effective and less toxic treatment options [21]. 
 
Oral drugs 
Teriflunomide is the metabolite of leflunomide, which has been approved for mild to moderate 
rheumatoid arthritis. Teriflunomide is given as 14 mg tablets once daily and the oral 
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bioavailability is almost 100% [41]. It inhibits the rate-limiting mitochondrial enzyme in de 
novo pyrimidine synthesis dihydroorotate dehydrogenase (DHODH) [41]. This leads to 
reduced proliferation of cells that need de novo synthesis of pyrimidine to divide. A salvage 
pathway independent of DHODH is enough for resting lymphocytes, however fast-
proliferating cells such as activated lymphocytes are dependent on de novo synthesis thus being 
a selective target of teriflunomide [42]. Other immunological mechanisms of teriflunomide 
have been suggested [41]. 
In two phase III trials in RRMS [43,44] teriflunomide reduced the ARR compared to placebo 
by 31%–36%, the MRI gadolinium enhancing lesions by about 80% and the rate of disability 
progression by 26%–27%. Teriflunomide had similar effects on the ARR and on time to a new 
relapse or termination of treatment compared with subcutaneous IFNβ-1a [45]. Teriflunomide 
has been tested in a randomized, double-blind, placebo-controlled trial on clinically isolated 
syndrome (CIS) patients with silent MRI lesions [46] and it delayed the time to a second relapse 
and a reduction in new MRI lesions. Teriflunomide is generally well tolerated, however 
common adverse events include alanine aminotransferase (ALT) increase, headache, diarrhoea, 
hair thinning, and nausea [47]. These are usually mild-to-moderate in intensity and are self-
limiting [47]. ALT elevation is the most common reason for treatment discontinuation and a 
relatively frequent (every second week) ALT screening during the first 6 months of treatment 
and thereafter every second month is recommended [47]. 
Delayed-release dimethyl fumarate (DMF) is the most recently approved oral DMT for RRMS. 
DMF is administered as a 240 mg capsule twice daily. Its mechanisms of action are not 
completely understood; however, data suggest they are mediated via the activation of the 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway [48]. DMF was compared to placebo 
in two phase III trials in RRMS [49,50] and it reduced the ARR by 44%–53%, the MRI 
gadolinium-enhancing lesions by about 75%–94% and the rate of disability progression by 
22%–32% [51]. DMF reduced the ARR by 24% and the rate of disability progression by 17% 
compared to GA [50], however the differences were not significant and the study was not 
powered to detect statistically significant differences in treatment effect. An interim analysis 
of an ongoing long term extension of the phase III trials showed that treatment with DMF was 
followed by continuously low clinical and MRI disease activity [52]. Common adverse events 
include flushing, nausea, diarrhoea and abdominal pain [51], are usually transient and mild to 
moderate in severity and can limit patient tolerance of DMT [53]. The treatment may induce 
leucopenia and increase liver transaminases, and regular blood tests are therefore 
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recommended. Prolonged severe lymphopaenia (<500 cells/mm3) has been suggested as a risk 
factor for PML [54]. In 2014, a case of PML was reported in a patient treated with DMF [55]. 
Four other PML cases have been previously reported in patients with psoriasis who had 
received fumaderm [56]. In JCV-positive patients with persistent lymphopaenia, DMF should 
be stopped. Up to now, PML has not been observed during DMF therapy without lymphopaenia 
and in the presence of appropriate monitoring and drug-discontinuation rules [57]. 
Fingolimod was the first of the oral agents for relapsing forms of MS to be approved by the 
FDA in 2010. Fingolimod is administered as a once-daily 0.5-mg capsule. Fingolimod is a 
nonselective sphingosine-1-phosphate (S1P) receptor modulator [58,59]. It acts as a functional 
antagonist, by internalising and degrading the S1P1 receptor on lymphocytes (a receptor 
responsible for T lymphocyte exit from the lymph nodes, circulation, and T cell 
differentiation)[58]. This leads to sequestration of T lymphocytes in secondary lymphatic 
tissues and thus reduces inflammation in MS [60]. An additional direct effect on the CNS has 
been suggested by animal studies [60].  
In two phase III trials in RRMS fingolimod compared to placebo educed the ARR by 48%–
55%, the MRI gadolinium-enhancing lesions by more than 80% and the rate of disability 
progression by 25%–30% [61]. Compared to IFNβ-1a 30 lg intramuscularly once weekly 
fingolimod reduced ARR by 52%, the MRI gadolinium-enhancing lesions by more than 50% 
and the rate of disability progression by 25% [62]. In a phase 3 trial in PPMS fingolimod failed 
to delay disability progression compared to placebo [63]. 
Common adverse events include upper respiratory tract infection, diarrhoea, cough, headache, 
and back pain [64]. Because it can cause bradycardia and atrioventricular block at first 
administration it is recommended to have electrocardiogram monitoring continuously for 6 h 
after the first dose [65]. After one death due to a fulminant primary varicella zoster in one of 
the phase III trials [66], screening for previous varicella zoster infection is advised in patients 
due to start fingolimod, and vaccination is recommended if negative. Rare adverse events 
include elevated liver enzymes and macular oedema and bloods and ophthalmological follow-
up are recommended [67]. 
Agents in trial 
Monoclonal antibodies 
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Three anti-CD20 agents (rituximab, ocrelizumab, and ofatumumab) that deplete pre-B cells 
and mature B cells without affecting plasma cells or progenitor cells in the bone marrow have 
been studied in MS [23]. Rituximab is a human–mouse chimeric monoclonal antibody against 
CD20. Rituximab has been used off label for MS as well as neuromyelitis optica. Rituximab 
has been approved to treat B cell lymphomas, rheumatoid arthritis, Wegener’s polyangiitis and 
microscopic polyangiitis [23]. In a phase II double-blind, placebo-controlled trial rituximab 
reduced new MRI gadolinium-enhancing lesions by 91% and the proportion of patients with 
relapses [68]. 78% of treated patients experienced an infusion-related adverse effect. Infection 
incidence was similar in both groups [68]. A phase II trial of rituximab in PPMS failed to meet 
its primary endpoint of delaying confirmed disability progression [69] and showed a 3.5% 
increase in risk of serious infections in the treated arm. In patients using rituximab for other 
indications, PML cases have rarely been reported [70]. Although rituximab rapidly and 
consistently decreases the numbers of peripheral CD20+ and CD19+ cells [71], a small phase 
II trial of intrathecal rituximab was terminated early because of low efficacy on the CSF 
biomarkers [72]. Rituximab induced an incomplete and transient depletion of B cells in the 
CSF, whilst the effects on peripheral B cells were complete and lasting.[72]. No phase III trials 
of rituximab for MS have yet been performed. Some suggest rituximab can be an option in 
RRMS patients who have failed to respond to first- and second-line therapies, in those with 
concomitant autoimmune disorders  [73] or in people with stable RRMS who switch from 
natalizumab to other DMT due to increased PML risk[74]. 
Ocrelizumab and ofatumumab are humanized anti-CD20 monoclonal antibodies. In a phase II 
placebo-controlled RRMS trial [75] two doses of ocrelizumab met the primary outcome of 
reducing the number of MRI enhancing lesions.  Infection side effects were equivalent between 
the two groups, but more infusion related side effects occurred in the ocrelizumab group than 
in the placebo arm. Two phase 3 clinical trials (OPERA I and II) for relapsing remitting MS 
were completed in 2015 [76]. The trials compared intravenous ocrelizumab 600 mg every 6 
months to subcutaneous IFNΒβ-1a. The studies reported that ocrelizumab reduced the annual 
relapse rate by 46% in OPERA I and by 47% in OPERA II [76]. Also, they showed a reduction 
of clinical disability by 40 %, as measured by the EDSS. Ocrelizumab reduced the number of 
T1 gadolinium-enhancing lesions in the brain by 94%, and 95% respectively [76]. Additionally, 
it resulted in a 77% and 83% reduction of hyperintense T2 lesions compared with IFNΒβ-1a. 
At 96 weeks, 47.9% of patients treated with ocrelizumab in OPERA I and 47.5% in OPERA II 
achieved the composite measure of ‘no evidence of disease activity’ (NEDA) defined as no 
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MS relapses, no confirmed disability progression, and no new or enlarging T2 or gadolinium-
enhancing T1 lesions, compared to 29.2% and 25.1% of patients treated with IFNΒβ-1a [77]. 
A recent phase III clinical trial (ORATORIO) tested ocrelizumab for primary progressive MS 
and compared intravenous ocrelizumab 600 mg every 6 months to placebo [78]. The primary 
endpoint was time to onset of 12-week confirmed disability progression (CDP), while 
secondary endpoints included time to onset of 24-week CDP; change in timed 25-foot walk, 
T2 lesion volume, change in whole brain volume and safety [78]. Ocrelizumab was the first 
trialed drug to meet primary and key secondary efficacy outcomes in a phase III PPMS study. 
Ocrelizumab significantly reduced the relative risk of 12-week CDP by 24% and 24-week CDP 
by 25% [78], decreased the volume of T2 hyperintense lesions and reduced the whole brain 
volume loss compared with placebo [78]. The frequency of adverse events and serious adverse 
events was similar in both groups [78]. The results of the OPERA I, OPERA II and 
ORATORIO trials will be submitted for the approval of ocrelizumab to the FDA. 
Ofatumumab is a fully human monoclonal antibody currently used for lymphocytic leukemia, 
which interacts with the early activation of the B lymphocyte and has lower potential for 
antigenicity. It was tested in a small phase II clinical trial with promising results, showing a 
99% reduction of MRI activity, with no serious adverse events [79]. A larger phase 2 trial, the 
MIRROR trial, tested the safety and effectiveness of ofatumumab compared to placebo in 232 
patients with RRMS [80]. This study also showed a 90% reduction of MRI lesions after 12 
weeks of treatment [80]. Five serious adverse events were reported in the 60mg dose regimen, 
but no cases of PML or opportunistic infections were reported [80]. The authors concluded the 
results support the further study of ofatumumab in clinical RRMS trials [80]. 
Cladribine 
Cladribine is a cytotoxic drug, an adenosine deaminase-resistant purine nucleoside, used as a 
first-line chemotherapeutic agent in the treatment of hairy cell leukemia and other neoplasms, 
in its parenteral formulation [81]. Cladribine enters cells via purine nucleoside transporters 
[82]. Cladribine works preferentially on lymphocytes and monocytes by disrupting cellular 
metabolism resulting in cell death [83], being incorporated into the DNA of the dividing cells. 
It selectively depletes the number of circulating T cells and B lymohocytes, having only a 
minor effect on NK cells [84]. The study of cladribine in MS started more than 20 years ago. 
Intravenous cladribine was initially evaluated for progressive MS (PPMS, SPMS) in two 
randomized double-blind clinical trials [85,86] with some promising results. Later, cladribine 
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was tested as an oral agent for RRMS, tablets being taken in two cycles of few days per year 
[84]. Cladribine for RRMS was tested in the placebo-controlled CLARITY trial and reduced 
both the frequency and severity of relapses, and suppressing the MRI enhancing lesions at 6 
months [87]. The recently reported results of a 120-week extension demonstrated that in a 
majority of patients, the clinical benefits on relapses and disability as well as on MRI outcome 
measures of 3.5mg/kg cladribine given in the first two years of the trial can be maintained for 
at least 4years [88,89]. ONWARD was a 2-year, randomized, double-blind phase IIb study of 
cladribine tablets (3.5mg/kg) as an add-on to IFN-β therapy in relapsing MS patients (including 
SPMS with ongoing relapses). The mean number of relapses was lower (23%) in patients 
treated with cladribine 3.5mg/kg and IFNβ than in patients on placebo plus IFNβ (56%) [90]. 
The mean numbers of new enhancing T1 lesions and active T2 were reduced in the 
cladribine+IFNβ treatment arm vs. placebo plus IFNβ [90]. In the phase III trial ORACLE 
(Oral Cladribine in Early Multiple Sclerosis) 616 CIS patients received 1:1:1 cladribine 5.25 
mg/kg, cladribine 3.5 mg/kg, or placebo [91]. Both doses of cladribine considerably delayed 
MS diagnosis compared with placebo [91]. A more recent analysis applied the 2010 McDonald 
criteria to the patient cohort at baseline and showed that the risk of further relapse and disability 
worsening was significantly reduced with cladribine 3.5 mg/kg compared to placebo [92]. 
Cladribine failed to get regulatory approval by the EMA because of concerns over the risks of 
cancers in the CLARITY active arm [93]. Cladribine was used for RRMS treatment in 2010 in 
Russia and Australia, but was withdrawn afterwards. However, a recent meta-analysis of phase 
III trials of licensed DMTs for RRMS and the CLARITY trial did not support an increased 
cancer risk from cladribine in the doses used in CLARITY and ORACLE MS, which 
previously contributed to refusal of market authorization of cladribine by EMA [94]. The 
authors concluded that longer-term follow-up is required to assess the safety profile of both 
cladribine or of the currently approved DMDs, to definitively assess cancer risk [94]. 
PREMIERE (NCT01013350), an observational prospective study of patients who have 
participated in clinical trials with cladribine or other DMTs is ongoing [94]. 
Laquinimod 
Laquinimod is an orally available carboxamide derivative, derived from linomide, a drug that 
was proved to reduce activity in RRMS, but with the cost of severe adverse events [95]. 
Laquinimod was or currently is tested for neurodegenerative disease such as Huntington’s 
disease and also for relapsing remitting and progressive MS [96]. Studies on the animal model 
of MS (experimental autoimmune encephalomyelitis, EAE) showed that laquinimod decreased 
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inflammation, demyelination and axonal injury [97]. It appears to reduce infiltration of CD4+ 
T cells and macrophages into the central nervous system (CNS), it also seems to increase the 
serum level of brain-derived neurotrophic factor which may protect against neuronal injury 
[98]. Laquinimod efficacy in RRMS patients has been assessed in two Phase III trials, 
ALLEGRO (Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis) 
[99] and BRAVO (Benefit–Risk Assessment of Avonex and Laquinimod) [100]. In ALLEGRO 
laquinimod was compared to placebo and showed a modest, but significant reduction of the 
annual relapse rate, and also a reduced rate of progression [99]. Initially the primary outcome 
measure of reducing annual relapse rate in BRAVO was not reached [100], but following an 
adjustment for an imbalance between the groups in the number of patients with enhancing 
lesions and of mean T2 lesion volume, both predictors of relapses, a reduction in relapse rate 
in the laquinimod arm (21% reduction vs placebo, p=0.026) was obtained. Overall laquinimod 
had more pronounced effects on disability progression and brain atrophy than on relapses and 
new MRI lesion formation [101]. Two ongoing studies are evaluating the safety and efficacy 
of laquinimod: CONCERTO (phase III, RRMS; NCT01707992), and ARPEGGIO (phase II, 
PPMS; NCT02284568). Both aimed to compare two doses of laquinimod, 0.6 and 1.5 mg/day, 
to placebo, however, in January 2016 TEVA announced the discontinuation of higher doses of 
laquinimod after the occurrence of cardiovascular events (none fatal), in eight subjects [102]. 
The study of lower-dose laquinimod will continue in both trials. 
Siponimod and ozanimod 
Siponimod (BAF312) is an oral modulator of sphingosine more selective than figolimod - acts 
selectively on S1P-1 and S1P-5 [103]. In a phase II trial in RRMS, siponimod was shown to 
reduce brain MRI lesions and relapses by up to 80 % compared to placebo [104]. The results 
of a phase III trial in SPMS (NCT01665144) were reported at the 32nd ECTRIMS Congress in 
London in September 2016. Patients with SPMS on siponimod had the risk of 3-month 
confirmed disability progression reduced by 21% compared with patients on placebo (p=0.013) 
Another oral selective S1P receptor modulator, ozanimod, was recently successfully tested in 
a phase 2 trial with positive MRI outcomes [24]. 
Agents in trial for progressive MS 
Finding effective treatments for progressive MS is a major priority and a challenge. The current 
treatment candidates and approaches for progressive MS have been recently reviewed in detail 
by Shirani et al [105]. An important point in testing drugs for progressive forms of MS is to 
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adapt trial methodology and clinically meaningful outcomes to this particular phenotype of 
MS, based on lessons learned from prior clinical trials [106]. 
It has been hypothesized that high-dose biotin can act on demyelinating axons by increasing 
energy production promoting synthesis of myelin [107]. Treatment with high-dose biotin was 
tested in an open-label pilot study [108] and a randomized, double-blind, placebo-controlled 
trial in progressive MS (23 and 154 patients, respectively) [109]. Both studies reported positive 
results on disability progression and a good safety profile [107]. Biotin can interfere with some 
laboratory tests (eg. false positive or negative thyroid tests [110,111]) and teratogenicity was 
reported in rabbits. Further studies are needed to clarify the duration of response to biotin over 
time and the responder profile in people with progressive MS. 
Autologous Bone Marrow Transplantation 
Hematopoietic stem cell transplantation (HSCT) has been reviewed in detail elsewhere [112-
116]. Studies on animal models showed that strong immunosuppression followed by syngeneic 
bone marrow transplantation can induce long term antigen-specific tolerance [117]. In the last 
15 years, due to the high rate of complications related to the procedure, autologous bone 
marrow transplantation was reserved only to MS patients that failed all other therapies and had 
a poor prognosis [116]. There is evidence that high-dose immune ablation and autologous 
HSCT could renew the immune system repertoire and reinforce immune tolerance mechanisms 
[118] thus having a clinical impact. Phase I clinical trials have shown that autologous 
hematopoietic stem cell transplantation may improve the quality of life of MS patients 
[112,116]. A recent phase II trial of HSCT vs mitoxantrone in RRMS and SPMS showed that 
HSCT reduced the number of new T2 and enhancing lesions and the AAR as compared to 
mitoxantrone [119]. In a very recent phase II trial, 70% of the patients who received an 
aggressive immune-ablative treatment followed by a HSCT graft depleted of autoreactive 
lymphocytes did not have any signs of disease activity (relapses, new MRI lesions, or EDSS 
progression) after a median follow-up of 6-7 years [120]. Although these results are promising, 
and progress has been made over the last decade in mitigating risks, there are many unknowns 
regarding the use of HSCT as a possible second-line therapy for refractory MS [121,122]. 
There is lack of consensus on the optimal conditioning regimen, patient selection (including 
the stage of the disease or what other prior treatments should they have failed to etc.) and the 
HSCT graft manipulation. Different conditioning regimens following the harvesting of the 
stem cells were used it the studies of autologous HSCT in people with MS [123]. The choice 
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of the conditioning regimens (myeloablative or non-myeloablative) can impact the outcomes 
both in terms of efficacy and toxicity [113].  The myeloablative conditioning regimens can 
completely eliminate the activated immune cells before the HSCT treatment, but would expose 
the patients to aplasia-related complications and death[113]. The use of lymphoablative but 
non-myeloablative conditioning regimens would be in keeping with “the rationale of auto-
HSCT […] to revive an antigen-naive immune system from the patient’s HSCs” [113] whilst 
mitigating adverse effects such as neurotoxicity[124].  Freedman recently noted that, although 
systematic comparison of regimens is lacking, the available data would suggest that the more 
intense conditioning regimens are followed by more durable responses but with more toxicity 
as well [121]. In their recently published study, Atkins et al removed the mature lymphocytes 
from the graft prior to transplantation by an ex vivo cell selection technology, avoiding graft-
mediated immune effects and thus apparently impacting disease activity[120]. However, the 
benefits of this procedure would only be seen with intense conditioning regimens which 
achieve a near-complete immune ablation[121]. Intense immune ablation with a regimen 
including a cytotoxic agent crossing the BBB would translate in an accelerated whole-brain 
atrophy rate, although the rate of atrophy would further slow to that expected from normal 
aging [125]. In a recent editorial, Sorensen suggests that, taking into account the HSCT benefit-
risk profile and the availability of highly-effective treatments with monoclonal antibodies 
which can achieve disease control in patients with active disease, intense immunosuppression 
with HSCT should remain a third-line therapy [122]. However, as Ellen Mowry notes in an 
editorial in the same journal [123], the comparison in terms of efficacy between the phase 3 
studies with monoclonal antibodies and the observational or single-arm HSCT studies does not 
provide evidence for or against the use of HSCT in MS, and further studies designed to 
comparing these treatments are warranted [123]. It is likely that the place of HSCT in MS will 
be re-evaluated over the next years, in light of the continuously-growing spectrum of available 
therapies and of new pragmatic, prospective, controlled multicentre trials.  
 
Remyelination strategies 
Remyelination occurs initially in MS lesions but is inadequate, and the mechanism of repair in 
the CNS fails with time, especially in chronic disease stages [126]. The differentiation of 
oligodendrocyte precursor cells (OPC) into mature cells is essential [126]. Remyelination 
develops in two steps: the colonization of the lesions by the OPCs, and the OPC differentiation 
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into mature oligodendrocytes able to generate functional myelin sheath [127]. The factors that 
could interfere with the OPC abilities to remyelinating in MS have been reviewed [128-130]. 
The immunological-OPC crosstalk has specific features in MS [131,132]. Age and disease 
duration matter. In older animals remyelination is significantly slowed, possibly because of the 
decreased response of monocytoid immune cells which are necessary for the clearance of the 
myelin debris that inhibit remyelination [133]. Neurodegeneration itself occurs early in the 
course of the disease and repeated episodes of demyelination could conceivably lead to local 
wearing out of myelin forming OPCs [134]. Most information on these processes comes from 
studies on animal models (EAE and the cuprizone model of MS) [135]. Remyelination can be 
promoted either by intrinsic (altering intrinsic signaling pathways) or extrinsic (acting on lesion 
environment) repair mechanisms [136,137].  
Intrinsic targets for remyelination. A way of promoting remyelination is modulation of specific 
signaling pathways such as Notch, the Wnt/β-catenin pathway and the retinoid X-receptor 
(RXR) signaling pathway [136] within oligodendrocytes to outweigh the inhibition of 
remyelination. Tocopherol derivative TFA-12, a synthetic long-chain fatty alcohol and a 
member of the vitamin E family, with anti-inflammatory properties [138] stimulates OPC 
differentiation and myelin repair in experimental models of MS through the inhibition of the 
Notch/Jagged1 intrinsic signaling pathway [138]. Lithium chloride stimulates myelin gene 
expression in oligodendrocytes via Wnt/β-catenin and Akt/CREB pathways [139]. 
Indomethacin, a non-steroidal anti-inflammatory drug that penetrates the blood brain barrier 
promotes the differentiation of OPC into mature cells, hence stimulating remyelination in 
animal models via modulation of Wnt/β-catenin pathway [140]. In vitro studies showed that 
the action of indomethacin relies on the GSK3β activity [140]. The nuclear retinoid X-receptor 
(RXR)-γ regulates positively the endogenous remyelination, by stimulating OPC 
differentiation [141]. RXR-γ binds to receptors inside the OPC, including the vitamin D 
receptor, and the complex RXR-vitamin D receptor enhances OPC differentiation [142]. 
Hence, vitamin D might have a role in remyelination. Finally, miconazole and clobetasol have 
been recently shown to enhance the generation of human oligodendrocytes from human OPC 
in vitro, possibly through mitogen-activated protein kinase and glucocorticoid receptor 
signalling, respectively [143]. 
Extrinsic targets for remyelination. Leucine-rich repeat and immunogloobulin domain-
containing 1 (LINGO-1) is a nervous-system specific transmembrane protein that may be a 
therapeutic target for remyelination. LINGO-1 is expressed by oligodendrocytes and was 
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shown to inhibit their ability to differentiate and myelinate; it is also expressed on axons where 
it limits axonal regeneration [144,145]. Antibodies blocking LINGO-1 promote OPC 
differentiation in demyelinated lesions, reduce axonal damage and restore function in EAE, 
cuprizone and lysolecithin animal models [146,147]. BIIB033 (Li 81; opicinumab) is a fully 
human monoclonal antibody that binds LINGO-1. BIIB033 enhances remyelination and 
restores function in animal models, although brain concentrations were of <0.5% of those in 
blood [148]. Anti-LINGO-1 antibodies have been the first remyelinating therapy evaluated in 
humans. Two randomized placebo-controlled phase I trials tested the safety, tolerability and 
pharmacokinetics of BIIB033 administered via IV infusion or subcutaneous injection in 
healthy volunteers and people with MS [149]. In these studies, one or two doses up to 100 
mg/kg were tolerated, with no serious adverse events and low immunogenicity [149]. RENEW 
was a randomized, double-blind, placebo-controlled phase II trial evaluating the ability of anti-
LINGO-1 to promote the repair of an acute optic nerve lesion after a first episode of acute optic 
neuritis and examining the effects on remyelination over 24 weeks through the measurement 
of the latency of nerve conduction between the retina and the visual cortex [150]. The treatment 
with anti-LINGO-1 in acute optic neuritis prevented the amplitude loss of the multifocal visual 
evoked potential observed in the fellow eye visual pathway of placebo-treated subjects over 32 
weeks and had some possible positive effects on amplitude preservation on the affected eye 
[150]. 
Another phase II trial (SYNERGY) testing the safety and effectiveness of opicinumab in 
association with IFNβ-1a injections once weekly in people with RRMS or SPMS 
(NCT01864148) has recently completed and the results presented at the 32nd ECTRIMS 
Congress in London in September 2016. The trial involved 416 participants receiving IFNβ-1a 
weekly and one of five different doses of anti-LINGO-1 per kg body weight or a placebo, once 
every 4 weeks for 72 weeks. The trial missed its primary endpoint (the percentage of subjects 
with confirmed improvement of neuro-physical and/or cognitive function and/or disability). 
Wang et al. differentiated OPCs from human induced pluripotent stem cells (iPS) and engrafted 
them in a myelin-deficient mouse model [151]. The transplanted OPCs differentiated into 
astrocytes and oligodendrocytes,  myelinated the brains of the animals, and increased their 
survival [151]. However, since MS is a multifocal disease it would probably require repeated 
transplantation of the OPC in all the demyelinated regions [134]. These techniques are still 
under study, and their safety and efficacy are yet unknown. OPC recruitment is reduced in MS 
lesions and chemotactic molecules such as Sema3A receptor neuropilin-1 could be a new group 
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of drug targets to improve remyelination [152]. It is not yet clear whether remyelination 
completely prevents neurodegeneration but it does appear to restore neuronal function and at 
least limit neuronal degeneration [134], therefore remyelination strategies are likely to be part 
of the MS treatments in the future (Table 2). 
Mesenchymal stem cells 
Mesenchymal stem cells (MSC) can be harvested from adult bone marrow and can be 
transplanted securely without the need for immunosuppression and with a low risk of aberrant 
proliferation. The IV route is preferred as it is less invasive has fewer adverse effects compared 
to intrathecal administration. It is likely that the potential therapeutic efficacy of MSC could 
be based on systemic effects as recently shown [153]. Mechanisms of action would include 
immunoregulation and anti-inflammatory changes of the cellular environment. The phase II 
trials of MSC in MS did not report major side effects related to treatment [154]. A phase 1/2 
open-safety clinical trial in patients with MS and with amyotrophic lateral sclerosis showed 
that intrathecal and intravenous administration of autologous MSCs is a clinically feasible and 
a relatively safe procedure which produced immediate immunomodulatory effects [155]. 
T-cell directed strategies  
It was suggested that the immune response in MS is directed at least in part against myelin 
proteins including basic protein (MBP), myelin oligodendrocyte protein (MOG) and 
proteolipid protein (PLP) [156-159]. Although there are differences in the activation state or 
precursor frequencies of T cells from patients with MS and healthy subjects, people without 
MS also have immune responses against such antigens. However, it was suggested based on 
indirect evidence that molecular mimicry, epitope spreading and bystander activation are 
possible mechanisms to initiate and maintain disease activity. Consequently, an alternative 
treatment approach in MS could aim to selectively restore self-tolerance to auto-antigens via 
immunization [160] and epitope-specific induction of T cell tolerization [161] or specifically 
by targeting regulatory T cells (Treg) signaling [162]. Antigen-specific therapies in MS have 
been reviewed [163,164]. A first phase I trial in humans published in 2013 showed that the 
antigen-coupled cell tolerization in MS is feasible and safe [165]. 
A number of animal studies and human clinical trials of T-cell vaccination in MS have been 
conducted and reviewed [166,167]. TCV include an attenuation step to preventing the 
encephalitogenicity of myelin-reactive T cells and is safe. Two phase II, placebo-controlled 
clinical trials of TCV in MS were reported [167,168]. Fox et al. showed that treatment with 
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myelin-reactive T-cells against up to six peptides of MBP, MOG and PLP was safe in 100 
RRMS and CIS patients, of which 44% were previously treated with DMTs [168]. Although 
no statistically significant clinical or radiological benefits were obtained when compared with 
the placebo arm, some post-hoc evidence of clinical efficacy in the active arm in the 
subgroup of patients DTM-naïve was seen[168]. Karussis et al. performed the first placebo-
controlled, double blind TCV trial in progressive MS[169]. 26 patients with relapsing-
progressive MS were included in the trial, of which 19 were treated with four injections with 
a mixture of attenuated autologous T-cell lines reactive to three to nine different peptides 
from the MBP, PLP and MOG sequences[169]. The TCV was safe, without serious adverse 
events. There was a strong clinical effect on relapses and disability measured by EDSS and 
the timed 10-meter walking test. The authors suggested that the use of multiple vaccinations, 
peptides and several anti-myelin cell lines accounted for the positive clinical effects obtained 
in this trial [169].  The ongoing or completed clinical trials using T-cell directed approaches 
are listed in Table 1. 
 
Drug repurposing in MS 
The failure to deliver successful neuroprotective therapies in MS has led to alternative 
strategies such as drug repurposing [170]. Vesterinen et al. list some of the factors contributing 
to this failure: “the incomplete understanding of disease biology, pathogenic complexity and 
heterogeneity, limited predictive value of animal models, […] a lack of established trial 
methodologies compounded by a wider context of chronically declining productivity in drug 
development based on target-based approaches, declining resources for drug development in 
the neurosciences, and the growing costs of clinical trials” [170]. In a phase 2 trial, high-dose 
simvastatin compared with placebo reduced the annualized rate of whole-brain atrophy [171]. 
Encouraging recent data suggest that phenytoin in acute optic neuritis [172] and amiloride in 
PPMS [173] could have a neuroprotective effect. We and others showed that re-purposing 
molecules such as angiotensin converting enzyme inhibitors or retinoids can be effective in the 
animal model of MS or promote remyelination [141,174-176]. It is probable that repurposing 
drug development will play a bigger role in the future despite the inherent pitfalls which impact 
its feasibility [177]. 
Choice of treatment strategy 
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The best treatment strategy in MS is still debated. Escalation strategy implies starting with less 
effective but safer treatments and escalating to more efficacious but riskier DMTs if the 
inflammation is not controlled [178,179]. This approach would select only patients with a more 
active MS to be commenced on riskier drugs. The downside of this approach is that often in 
practice some patients have already accumulated some degree of disability at the time of 
escalation, which may be irreversible [180]. This disadvantage is taken into account by those 
advocating starting treatment with a more potent drug from the outset (induction strategy). This 
approach applied indiscriminately would in turn expose people with less active MS to 
unwanted drug side-effects. The treatment selection should take into account how aggressive 
and active the inflammation is; medications such as natalizumab and alemtuzumab would be 
preferred in people with active MS. However, alemtuzumab was EMA registered for patients 
“with active disease defined by clinical or imaging features” [29] and this allows treatment in 
people with early disease and moderate relapse rate if active disease is demonstrated (defined 
as at least 2 relapses within the prior 2 years). 
A new strategy aims to attain ‘no evidence of disease activity’ (NEDA). NEDA emerged as 
therapeutic expectations and targets evolved to enclose possible remission from evolving 
disease. NEDA is defined as absence of relapses, progression of disability and MRI activity 
such as new or newly enlarging T2 lesions and new enhancing lesions [181]. Achieving the 
NEDA status at 2 years has a good prognostic value over a 7-year period [182]. NEDA is 
criticized of not reflecting patients’ needs in clinical practice [183]. The absence of brain 
atrophy measured by MRI as a marker of neuroaxonal loss was proposed as an additional 
criterion for NEDA (NEDA-4 )[184]. The effects of MS treatments on disability progression 
relate with the effects on atrophy over 2 years, independently from the effect on active MRI 
lesions[185]. This would support the use of brain atrophy as a surrogate marker of disability 
progression [186]. However, routinely assessing atrophy is difficult due to logistical and 
technical restraints (for example variability between scans and scanners). As Zimmsen et al. 
note, “the increasing focus on NEDA as an aim of MS therapy implies that regular, systematic, 
monitoring should be a central aspect of the management of the condition” [179]. This raises 
the issue of disease monitoring: how often and what measures to use. How each of the detected 
MRI changes would entail a specific and timely change in the treatment strategy is still a matter 
of debate. Moreover, it is not clear yet if an escalation approach aiming of achieving NEDA 
would certainly improve disease outcome over the long term [180]. Possibly additional 
outcome measures (ie. cognitive impairment) and MS patient reported measures may prove 
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useful to identify non-responders to DMT and therefore could be candidate measures to be 
incorporated in NEDA. Nevertheless, data from clinical trials back the idea of a benefit of early 
initiation of treatment in MS [187-190] [191]. Early treatment would have an impact on long-
term prognosis in terms of mortality [192]. Although it is intuitive that MRI measures can 
reflect breakthrough disease, there is a lack of clinical consensus on the quantitative aspects of 
these measures. Two new enhancing lesions were predictive of disability worsening in a 15-
year follow-up study of patients enrolled in a pivotal IFNβ trial [193]. A recent systematic 
review of studies examining differential response to IFNβ showed that patients with 2 or more 
new hyperintense T2 lesions or new gadolinium-enhancing lesions had significantly increased 
risk of both future relapses and progression [194]. The Rio score was developed by the 
Barcelona group and included the number of clinical relapses, disability progression and new 
T2 or enhancing MRI lesions [195]. Patients with RRMS who met at least two of these criteria 
(but not relapses or MRI criteria alone) had a higher risk of having relapses or disability 
progression in the next 2 years. A new version of the Rio score was validated in the original 
data set and classified patients in low-, medium- and high-risk of progression based on relapses 
or MRI activity only [196,197]. A study by Prosperini et al. suggested that MRI alone could be 
a 4-year good predictor of outcome after the first year of treatment with IFNβ-beta [198]. While 
changes in clinical and MRI measures of disease activity can lead to a treatment change, the 
disease-related outcomes reported by the patient could too. It is probable that over the next 
years more information from real-life experience regarding specific drug efficacy, long term 
safety concerns, cost-benefit considerations and patient-perceived therapy burden, will be 
available. 
 
Five year view 
In a recent review, Coles [180] describes the current era of treatments of MS as ‘the era of 
complexity’. This followed the ‘era of nihilism’ when no DMT were available and the ‘era of 
modest efficacy’ which started after 1993 with the IFNβ-beta and glatiramer acetate trials 
(which were proven modestly effective on relapse rate but safer than immunosuppressants such 
as mitoxantrone and cyclophosphamide) [180]. The current ‘era of treatment’ started with the 
introduction of natalizumab and the first reports of PML as the main drug side-effect which 
mitigated the enthusiasm for this medication [180]. Over the next decade, the oral drugs 
fingolimod, dimethyl fumarate and teriflunomide, and the injectable alemtuzumab have 
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become available in many countries. As mentioned above, it is likely that daclizumab and 
ocrelizumab will soon follow. The development of the newer therapies for MS raises new 
challenges to the treating neurologist. The questions the doctors are facing regard the correct 
sequence of drugs to be offered to a given patient; and the appropriate and safe sequence of 
switching between drugs. Since all the available DMTs are directed against the inflammatory 
phase of MS, the major unmet need at this time is for treatments for progressive disease. It is 
likely that in the next and fourth era of DMTs in MS  the efforts of tackling progressive disease 
will become successful [180]. It is also likely that more evidence would become available to 
support the different strategies for the sequencing and timing of treatments. Clarifying the 
monitoring strategies for adverse effects and breakthrough MS would be crucial. The 
development of radiological and biological biomarkers could allow in the future personalizing 
treatment  and precision medicine in MS [199]. Features such as detection of central veins in 
the MS lesions could improve diagnostic quality [200]. Biomarkers such as neurofilament light 
chains [201] and chitinase 3-like proteins in the CSF [202] could be used as potential prognostic 
markers after CIS while markers such as CSF lipid-specific IgM bands[203] and L-
selectin[204] could be incorporated in the PML risk stratification in patients under natalizumab 
[203]. 
Over the past 50 years, the largest impact on increasing life expectancy in the general 
population came from primary prevention. MS is the result of the interaction between the 
genetic background and environmental factors. Among the latter, vitamin D deficiency, 
infection with the Epstein-Barr virus (EBV), cigarette smoking, obesity in youth and lack of 
exposure to intestinal parasites are environmental predictors of MS risk [205]. Considering that 
research into preventing MS currently has a high priority, developments in prevention 
strategies are anticipated. Studies of anti-EBV vaccination in people at risk of developing MS, 
clinical trials of smoking cessation in MS and more clinical trials with vitamin D are expected. 
The prevalence of MS is inversely correlated with helminth infections and studies of helminth 
treatments in MS could help in understanding the mechanisms of parasite-induced 
immunomodulation [206]. 
Treating the right patient with the right drug early in the disease course, before disability has 
been acquired, could yield long term benefits. It is realistic to expect over the next decade more 
data from approaches aiming to prevent MS and on methodologies to protect neurons or 
promote remyelination. Finally, the future of MS treatments would rely on a better 
understanding of the immunopathogenesis of MS.  
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Key issues 
 MS is an immune condition of the CNS characterized by focal damage (inflammation) 
which manifests clinically mainly as relapses and diffuse damage (neurodegeneration) 
and brain volume loss) which are both responsible for disability. 
 There is no cure for MS. A number of disease modifying treatments (DMTs) have been 
approved which are primarily directed against inflammation. There are a number of 
additional DMTs in trial or being submitted for approval. 
 There are different treatment strategies in MS. In patients with active disease despite 
treatment it has been recommended to switch early to a therapy of higher efficacy. 
 Despite important advances in the treatment of MS, the burden of progressive disability 
and premature mortality remains considerable. There is no currently approved 
treatment for progressive MS, but recently a monoclonal antibody (ocrelizumab) was 
reported to be effective in a primary progressive MS trial. 
 New treatment strategies involving remyelination or neuroprotection are under study. 
It is likely that the next decade brings substantial changes in the understanding and 
ways of approaching the treatment in MS.  
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